Lexaria Bioscience Corp. LXRP Archives - Page 18 of 27

FridayJul 20, 2018 11:38 am

QualityStocksNewsBreaks – Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQX: LXRP) DehydraTECH™ Platform Continues to Demonstrate its Value

Lexaria Bioscience (CSE: LXX) (OTCQB: LXRP) believes that in the future, up to 80 percent of its total revenue could stem from licensing deals for its patented DehydraTECH™ delivery technology. An article discussing the company reads: “The company’s patented DehydraTECH™ is key to LXRP’s valuation. The technology is being tested in human clinical studies for the delivery of cannabinoids through ingestible means. Results thus far have shown increased absorption rates with reduced time to enter the bloodstream and reported improvements in the taste and smell of edible products. … Lab tests on mice have shown a 50 percent improvement in…

FridayJul 13, 2018 10:47 am

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Sees Potential in Alternative Nicotine Delivery Method

Lexaria Bioscience (CSE: LXX) (OTCQB: LXRP) believes that its patented technology, DehydraTECH™ has the potential to transform nicotine use by offering a delivery method that may be an effective alternative to the traditional inhalation. An article discussing the company reads: “Although inhalation is an effective delivery mechanism – much more so than non-enhanced edible ingestion – it is dangerous. The toxins released during combustion are harmful and can potentially kill the user. Edible ingestion eliminates the toxins caused by lighting up. While inhalation is fast, traditionally, ingestion has not been. However, the use of DehydraTECH™ speeds things up to make…

FridayJul 06, 2018 10:13 am

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Out-licenses Disruptive Delivery Technology to Strategically Build Cash Flow

Lexaria Bioscience (CSE: LXX) (OTCQB: LXRP) has been strategically out-licensing its disruptive delivery technology and focusing on R&D to improve its value and increase cash flow. An article further discussing the company reads: “Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) CEO Chris Bunka said in a recent CFN Media Group interview that his company has gained in value and cash flow, purposely keeping its cash burn rate down and evaluating technology applications for both cannabis and other sectors (http://ibn.fm/eaQDZ). … Bunka explained that LXRP is respecting its shareholders in terms of lowered spending and increasing its valuation, purposely maintaining its…

FridayJun 29, 2018 9:27 am

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Files New Patent Application Following Breakthrough Discovery of Enhanced Drug Delivery to Brain Tissue

Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) this morning announced that it has filed a new patent application with the United States Patent and Trademark Office ("USPTO") for innovation in treatment options related to central nervous system disease or disorders including viral infection, cancer, neurodegenerative disorders, ADHD, anxiety, depression, OCD, schizophrenia, Alzheimer's, Huntington's, Parkinson's, neuropathic pain and more. The company reached a breakthrough discovery during recent laboratory testing that demonstrated significantly enhanced drug delivery to brain tissue. Evidence from the study showed unexpected effectiveness in crossing the blood-brain barrier ("BBB") which Lexaria is investigating more extensively, leading to the company's…

ThursdayJun 28, 2018 2:52 pm

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Continues to Build Patent Portfolio

Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) is in the process of preparing new patent application filings and expects to receive more patent awards this year to add to its collection of over 40 patent awards or applications from 40 countries globally. A recent article discussing the company reads: “The total, once granted, would be four patents in the U.S. and four in Australia. All eight are for the family of “Food and Beverage Compositions Infused With Lipophilic Active Agents and Methods of Use Thereof.” The development represents the first time that LXRP has expanded its patent protection outside of…

TuesdayJun 26, 2018 12:10 pm

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Pursuing Diverse Applications for DehydraTECH™ Licensing

Lexaria will license in any of the 40 countries where its technology already has a patent or is patent-pending Company sees up to 80 percent of its future revenues coming from licensing DehydraTECH proprietary ingestion delivery technology DehydraTECH™ has applications for processed foods, tobacco industry, pharmaceutical companies, NSAIDs, supplements and beverages Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) has a wide variety of licensing applications for its patented DehydraTECH™ delivery technology. It is already licensed to Nuka Enterprises LLC, maker of “1906” brand cannabis chocolates (http://ibn.fm/lF00P). Chris Bunka, CEO, emphasizes that his company’s technology applies to far more than just the…

WednesdayJun 20, 2018 1:40 pm

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Continues to Develop Potential Uses of Patented Technology

Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) has developed and is already licensing DehydraTECH™, a technology that improves the bio-absorption and bioavailability of ingestible substances. A recent article discussing the company’s unique technology reads: “Application of the technology extends beyond nicotine to non-psychoactive cannabinoids, vitamins and non-steroidal anti-inflammatory drugs (NSAIDs), and Lexaria has licensed the technology to a number of companies, including chocolate maker Nuka Enterprises; cannabis beverage manufacturer GP Holdings; and Biolog, which markets hemp-based, cannabidiol (CBD)-infused products and vitamins. Lexaria is expected to sign 6-12 more licensing agreements in 2018. These are typically six-figure contracts in the first…

TuesdayJun 19, 2018 11:43 am

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Ending the Need to Light-Up

Lexaria is ahead of the game in the expected second flow of investment capital in “plant-to-bloodstream” companies Company’s DehydraTECH™ technology has the potential to revolutionize nicotine use, eliminating the major cause of related deaths by shifting demand away from smoking cigarettes DehydraTECH™ makes it possible to experience most of the positives associated with inhalation while eliminating the negatives, helping to make lighting up a thing of the past Within the cannabis industry, the initial flow of investment capital has been toward ‘seed-to-plant’ companies. As the next stage of investment is expected to be ‘plant-to-bloodstream’, companies such as Lexaria Bioscience Corp.…

ThursdayJun 14, 2018 1:34 pm

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Appeals to Investors with Slow Burn Rate, Model that Goes Beyond Cannabis Sector

Chris Bunka, CEO of LXRP, in an interview with CFN Media Group, stated that his company’s cash flow is strengthening from licensing and R&D, with technology applicable to other sectors Bunka noted that LXRP’s 71 million share count is kept purposely low relative to others in the category, with its valuation growing by “close to 2,000 percent” over the past several years LXRP’s goal is to slow disease and make cannabis acceptable to the general population Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) CEO Chris Bunka said in a recent CFN Media Group interview that his company has gained in…

ThursdayJun 14, 2018 12:04 pm

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Strategically Positioned for Growth in Cannabis Industry

Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) recently entered into a five-year semi-exclusive licensing agreement with GP Holdings LLC to develop a high performing cannabis beverage to be sold in California, a flourishing cannabis marketplace. A recent article discussing the company’s unique technology reads: “The semi-exclusive agreement gives LXRP the ability to offer other licensee partners the option of utilizing GP’s formulation and manufacturing expertise to produce cannabis-infused beverages throughout California. With the California cannabis-beverage market anticipated to be one of the largest edible product segments, LXRP is strategically positioned for continued growth within the cannabis industry.” To view the…

Site Search

Company Search

Tag: Lexaria Bioscience Corp. LXRP